Cargando…
Bevacizumab for the Treatment of Recurrent Glioblastoma
Despite advances in upfront therapy, the prognosis in the great majority of patients with glioblastoma (GBM) is poor as almost all recur and result in disease-related death. Glioblastoma are highly vascularized cancers with elevated expression levels of vascular endothelial growth factor (VEGF), the...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Libertas Academica
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095028/ https://www.ncbi.nlm.nih.gov/pubmed/21603247 http://dx.doi.org/10.4137/CMO.S7232 |